

Title (en)
CANCER IMMUNOTHERAPY USING POLYCOMB PROTEINS

Title (de)
KREBS-IMMUNTHERAPIE MITTELS POLYCOMB-PROTEINEN

Title (fr)
IMMUNOTHERAPIE DE CANCER UTILISANT DES PROTEINES POLYCOMB

Publication
EP 1572231 A2 20050914 (EN)

Application
EP 03767982 A 20031210

Priority
• GB 0305403 W 20031210
• GB 0228900 A 20021211

Abstract (en)
[origin: WO2004052392A2] The invention relates to the use of polycomb group proteins as a tumour-associated antigens. Polycomb group proteins are highly involved in body architecture development, haematopoiesis and cell cycle control. Aberrant expression of polycomb proteins has been linked with haematological malignancies, mainly lymphomas. This invention relates to the use of these polycomb group proteins as antigens for cancer immunotherapy. Immunological responses can be raised against these proteins and such responses are active against polycomb protein over-expressing tumour cells.

IPC 1-7
A61K 39/002; **A61K 48/00**; **C07K 14/82**

IPC 8 full level
A61K 39/00 (2006.01); **C07K 14/82** (2006.01)

CPC (source: EP US)
A61K 39/001149 (2018.08 - EP US); **A61K 39/4615** (2023.05 - EP); **A61K 39/4622** (2023.05 - EP); **A61K 39/4644** (2023.05 - EP); **C07K 14/82** (2013.01 - EP US); **A61K 2039/53** (2013.01 - EP US)

Citation (examination)
• STEELE-JC ET AL.: "The polycomb group proteins, BMI-1 and EZH2, are tumour-associated antigens", BR J CANCER., vol. 95, no. 9, 3 October 2006 (2006-10-03), pages 1202-11
• PARKER-KC ET AL.: "Peptide binding to MHC class I molecules: implications for antigenic peptide prediction", IMMUNOL RES, vol. 14, no. 1, 1995, pages 34-57, XP008004263
• SELLERS-WR ET AL.: "The EZH2 polycomb transcriptional repressor--a marker or mover of metastatic prostate cancer?", CANCER CELL, vol. 2, no. 5, 20 November 2002 (2002-11-20), pages 349-50
• PITTET-MJ ET AL.: "Melan-A/MART-1-specific CD8 T cells: from thymus to tumor", TRENDS IMMUNOL, vol. 23, no. 7, July 2002 (2002-07-01), pages 325-8, XP004367739, DOI: doi:10.1016/S1471-4906(02)02244-5
• TROJAN-A ET AL.: "Functional detection of epithelial cell adhesion molecule specific cytotoxic T lymphocytes in patients with lung cancer, colorectal cancer and in healthy donors", LUNG CANCER, vol. 36, no. 2, May 2002 (2002-05-01), pages 151-8, XP002349229, DOI: doi:10.1016/S0169-5002(01)00478-0
• NAGORSEN-D ET AL.: "Natural T-cell response against MHC class I epitopes of epithelial cell adhesion molecule, her-2/neu, and carcinoembryonic antigen in patients with colorectal cancer", CANCER RES, vol. 60, no. 17, 1 September 2000 (2000-09-01), pages 4850-4

Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

DOCDB simple family (publication)
WO 2004052392 A2 20040624; **WO 2004052392 A3 20040812**; AU 2003292405 A1 20040630; AU 2003292405 A8 20040630; EP 1572231 A2 20050914; GB 0228900 D0 20030115; US 2006127408 A1 20060615

DOCDB simple family (application)
GB 0305403 W 20031210; AU 2003292405 A 20031210; EP 03767982 A 20031210; GB 0228900 A 20021211; US 53854605 A 20050610